Skip to main content

Table 3 Prognostic potential of PCa signatures

From: A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer

  P-values (compared to known PCa signatures) P-values (compared to random sets of genes)  
Dataset Signature STO CAM MSKCC STO CAM MSKCC Ref
CUZICK 0.00466 0.01610 2.10E-06 0.0182 0.0272 0.0000 22
TMCC11 0.00915 0.00479 0.000173 0.0305 0.0120 0.0018 This study
HES6 0.00544 0.00447 0.24900 0.0242 0.0126 0.5834 56
ROSS(100E) 0.17000 0.00720 0.06070 0.2609 0.0173 0.1388 34
IRSHAD 0.14100 0.04040 0.14500 0.2208 0.0552 0.2819 57
ONCOTYPEDX 0.05380 0.15600 0.20600 0.1126 0.1846 0.3586 25
SHARMA 0.46600 0.29700 0.60400 0.5489 0.3234 0.7237 58
  1. Left columns: Comparative TMCC11 and known PCa signatures prognostic potential. Performance scored by log-rank test p-value of the difference on time to BCR between high and low risk groups defined by the overall gene expression signature. Right columns: Comparative analysis for TMCC11 and known PCa signatures over performance against random signatures. For each signature, 10,000 equal size signatures were generated at random and evaluated for predicting early relapse by log-rank test p-value. An overall bootstrap p-value score was computed as proportion of random signatures performing better than the initial signature. For both analyses, the data is sorted by first principal component of the individual rankings of the 3 columns corresponding to the Cambridge, Stockholm and MSKCC datasets. The Ross (100E) signature corresponds to the genes selected based on transcriptome profiling only. See also Additional file 1: Tables S5 and S6 for a full list with additional signatures